Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PE-PE study of perioperative pembrolizumab for resectable oligometastatic kidney cancer
2024-512180-31-00Phase 2Authorised
- Sponsor
- Consorzio Oncotech
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in renal cell carcinoma (RCC) (2 arms), sponsored by Consorzio Oncotech. Primary endpoint: Relapse-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-512180-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512180-31-00.